yingweiwo

Ras

Ras

Ras related products

Structure Cat No. Product Name CAS No. Product Description
(S,R,S)-BBO-11818 V122259 (S,R,S)-BBO-11818 3029184-80-0 (S,R,S)-BBO-11818 is a KRAS inhibitor that can be used in cancer research.
2-羟基-1-萘甲醛 V51476 CFL-137 708-06-5 CFL-137 is a selective KRasG12C inhibitor.
ADT-1004 V128345 ADT-1004 1945941-72-9 ADT-1004 is the oral active prodrug of ADT-007.
Antineoplaston A 10 V11400 Antineoplaston A 10 91531-30-5 Antineoplaston A10 exists naturally in the human body and is an inhibitor (blocker/antagonist) of Ras.
Antitumor compound 5a V51547 Antitumor compound 5a 2907704-65-6 Antitumor compound 5a, has an IC50 value of 2.62 µM, meaning that it inhibits MCF-7 breast cancer cells.
ARS-1620 V3974 ARS-1620 1698055-85-4 ARS-1620 is a novel, potent, orally bioavailable and covalent inhibitor ofKRASG12C with antitumor activity.
BQU57 V1902 BQU57 1637739-82-2 BQU57, a derivative of RBC8, is a novel and selective GTPase Ral inhibitor relative to the GTPases Ras and RhoA.
CCG-203971 V3118 CCG-203971 1443437-74-8 CCG-203971 is a novel, 2nd generation small-molecule inhibitor of the Rho/MRTF/SRF [RhoA/myocardin-related transcription factor A (MRTF-A)] pathway with an IC50 value of 0.64 μM for SRE.
Daraxonrasib (RMC-6236) V51194 Daraxonrasib (RMC-6236) 2765081-21-6 Daraxonrasib (RMC-6236; RAS-IN-2; RMC6236;Compound A122) is a potent RAS(ON)MULTI inhibitor that may be utilized in cancer-related research.
Daraxonrasib racemate (RMC‑6236; RAS-IN-4) V143850 Daraxonrasib racemate (RMC‑6236; RAS-IN-4) 2765091-21-0 Daraxonrasib racemate (RMC‑6236; RAS-IN-4) is a RAS inhibitor with anti-tumor activity.
HRS-4642 V86765 HRS-4642 3033864-81-9 HRS-4642 is a selective KRAS(G12D) inhibitor (Kd=0.083 nM) with anti-cancer activity.
ISIS 2503 sodium scrambled negative control V138094 ISIS 2503 sodium scrambled negative control The ISIS 2503 sodium scrambled negative control is a negative control with the sequence of ISIS 2503 sodium salt scrambled.
K-Ras 抑制剂6 V2420 K-Ras inhibitor 6 2060530-16-5 K-Ras (G12C) inhibitor 6 is a novel, potent, allosteric, irreversible,/covalent cysteine-reactive small molecule KRAS G12C inhibitor with anticancer activity.
K-Ras-IN-1 V2944 K-Ras-IN-1 84783-01-7 K-Ras-IN-1 (formerly known as K-Ras-Inhibitor-1) is a novel small molecule K-Ras inhibitor that binds to K-Ras in a hydrophobic pocket that is occupied by Tyr-71 in the apo-Ras crystal structure, in other words, K-Ras-IN-1 binds directly to K-Ras between switch I and switch II and inhibit Sos-catalyzed K-Ras activation.
KRAS G12C inhibitor 20 V51438 KRAS G12C inhibitor 20 2640858-10-0 KRAS G12C inhibitor 20 is an inhibitor (blocker/antagonist) of KRAS G12C.
KRAS G12C inhibitor 57 V51429 KRAS G12C inhibitor 57 2821863-70-9 KRAS G12C inhibitor 57 is a novel, selective, and oral active inhibitor of KRAS G12C that has an IC50 of 0.21 μM in the KRAS G12C/SOS1 binding assay. KRAS G12C inhibitor 57 induces cancer cell apoptosis.
KRAS G12C inhibitor 58 V51435 KRAS G12C inhibitor 58 2915599-52-7 KRAS G12C inhibitor 58 is an inhibitor (blocker/antagonist) of KRAS G12C and may be utilized in cancer-related research.
KRAS G12C inhibitor 65 V138482 KRAS G12C inhibitor 65 3033305-77-7 KRAS G12C inhibitor 65 is a potent covalent KRASG12C inhibitor that captures KRASG12C in the GDP-binding state.
KRAS G12D inhibitor 25 V93256 KRAS G12D inhibitor 25 2768099-61-0 KRAS G12D inhibitor 25 (compound 148) is an inhibitor of KRAS G12C and HSP90α with IC50 of <0.1 μM and 0.1-1 μM, respectively.
KRAS G12D inhibitor 7 V51421 KRAS G12D inhibitor 7 2648552-34-3 KRAS G12D inhibitor 7 is a potent inhibitor of KRAS G12D (information is from patent WO2021108683, compound 114).
Contact Us